CTOs on the Move

Soundbite Medical Solutions

www.soundbitemedical.com

 
SoundBite Medical is a medical devices company that began operations in May 2015, with its R&D facilities in Sherbrooke and commercialization headquarters in Montreal, Quebec. The Company is developing and commercializing proprietary wire-based device and generator console that delivers safe shockwave energy within the cardiovascular system to treat chronic total occlusions.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Soundbite Medical Solutions raised $19.9M on 04/20/2018

Similar Companies

RubrYc Therapeutics

RubrYc Therapeutics is a biotechnology company that integrates chemistry and computation to decode therapeutically significant protein interfaces, revolutionizing the discovery of antibody-based drugs.

Broncus Technologies, Inc.

Broncus Medical, Inc. is a well-funded, commercial stage company based in San Jose, CA. The Company`s mission is to deliver navigation, diagnostic & therapeutic technologies to treat patients with lung disease. The Company has a comprehensive intellectual property portfolio with over 75 patents including those issued, licensed, and pending. Along with Broncus Medical`s focus on technological advancements, it is committed to providing outstanding value to patients, healthcare professionals, investors and employees.

Goodwin Biotechnology

Goodwin Biotechnology is a Fort Lauderdale, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pebble Labs

Pebble Labs Inc. is a biotechnology company developing solutions to safely and sustainably increase natural crop yield and food security. Our mission is to develop breakthrough disruptive technologies that address the greatest agricultural, aquacultural, and environmental challenges facing the globe.

ARCA biopharma

ARCA was founded on the belief that a precision medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of patients, can enable more effective therapies, improve patient outcomes and reduce healthcare costs. ARCA`s lead development program is intended to be a direct implementation of those ideas. Gencaro™ (bucindolol hydrochloride) is being developed as a potential treatment for atrial fibrillation (AF). ARCA has identified genetic variations in cardiac receptors that we believe may predict individual patient response to Gencaro™, giving Gencaro™ the potential to be the first genetically-targeted prevention treatment for AF. ARCA is also developing rNAPc2 as potential treatment for RNA-associated diseases, initially focused on COVID-19.